Similar articles

• Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

  Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Ceresoli GL, et al. J Clin Oncol. 2006 Mar 20;24(9):1443-8. doi: 10.1200/JCO.2005.04.3190. J Clin Oncol. 2006. PMID: 16549838 Clinical Trial.
• Pemetrexed combination improves mesothelioma survival.

  Kerr C. Kerr C. Lancet Oncol. 2005 Aug;6(8):548. doi: 10.1016/s1470-2045(05)70268-0. Lancet Oncol. 2005. PMID: 16094758 Clinical Trial. No abstract available.
• Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?

  Rusch VW. Rusch VW. J Clin Oncol. 2003 Jul 15;21(14):2629-30. doi: 10.1200/JCO.2003.02.043. J Clin Oncol. 2003. PMID: 12860935 No abstract available.
• Pemetrexed-cisplatin combination in mesothelioma.

  Reck M, Gatzemeier U. Reck M, et al. Expert Rev Anticancer Ther. 2005 Apr;5(2):231-7. doi: 10.1586/14737140.5.2.231. Expert Rev Anticancer Ther. 2005. PMID: 15877521 Review.
• An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.

  Zilembo N, Vitali M, Pietrantonio F, Platania M, Del Vecchio M, Bajetta E. Zilembo N, et al. Tumori. 2010 Nov-Dec;96(6):1031-4. Tumori. 2010. PMID: 21388071 Review.